Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Landos Biopharma To Present New Data On NX-13 From Phase 1B Trial In Ulcerative Colitis At United European Gastroenterology Week 2023 Congress

Author: Benzinga Newsdesk | September 19, 2023 08:14am

NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC)

 

NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected in Q4 2024

Posted In: LABP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist